21世纪经济报道记者季媛媛无论是卫材公司的仑卡奈单抗还是礼来的多奈单抗,患者一年的治疗费用均需超过10万元。高昂的治疗费用一度让不少阿尔茨海默病(AD)患者家庭在希望与绝望间徘徊,直到首版商保创新药目录为这种困境带来了转机。日前,在2025创新药高质量发展大会上,我国首版《商业健康保险创新药品目录》正式发布。两款近年来最具突破性的阿尔茨海默病对因治疗药物——仑卡奈单抗注射液和多奈单抗注射液双双入选...
Source Link21世纪经济报道记者季媛媛无论是卫材公司的仑卡奈单抗还是礼来的多奈单抗,患者一年的治疗费用均需超过10万元。高昂的治疗费用一度让不少阿尔茨海默病(AD)患者家庭在希望与绝望间徘徊,直到首版商保创新药目录为这种困境带来了转机。日前,在2025创新药高质量发展大会上,我国首版《商业健康保险创新药品目录》正式发布。两款近年来最具突破性的阿尔茨海默病对因治疗药物——仑卡奈单抗注射液和多奈单抗注射液双双入选...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.